MediciNova Posts Promising Data From COVID-19 Treatment Candidate

  • MediciNova Inc MNOV says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoints analyzed. 
  • The trial achieved statistical significance for one of the co-primary endpoints, the proportion of subjects free of respiratory failure. 
  • The trial also achieved statistical significance for the proportion of subjects discharged from the hospital.
  • Related: MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking.
  • 71% of subjects in the MN-166 group and 35% of subjects in the placebo group were free of respiratory failure at Day 7.
  • 71% of subjects in the MN-166 group and 47% of subjects in the placebo group had improved clinical status.
  • 65% of subjects in the ibudilast group and 29% of subjects in the placebo group were discharged from the hospital.
  • There were two deaths in the placebo group and no deaths in the MN-166 (ibudilast) group.
  • There were no serious adverse events related to ibudilast.
  • Price Action: MNOV shares are up 8.09% at $2.54 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!